[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
125 patients in the early stages of Parkinson's syndrome were randomized and subjected to prearranged treatment adaptation period. Subsequently they were treated with either a mean dosage of 444 mg levodopa and benserazide (47 patients) or a combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine (32 patients). Follow-up was done up to three years. Combined treatment permitted reduction of the levodopa dosage by 39%. As assessed by improvement of symptoms of Parkinson's syndrome in patients with a minimum treatment period of 1 or 3 years combined treatment was shown to be superior to monotherapy.